Non-inferiority Study of a Hydroxyapatite and Calcium Hypophosphite Toothpaste Compared With Two Comparator Toothpastes in Dentin Hypersensitivity
Double-blind, Randomized, Non-inferiority Clinical Study to Evaluate the Efficacy of a Toothpaste Containing 20% Hydroxyapatite (HAP) and 2% Calcium Hypophosphite (CaP) Compared With Two Comparator Toothpastes by Assessing the Impact on Symptoms of Dentin Hypersensitivity Over a Study Duration of 56 Days (8 Weeks), as Well as Its Safety and Tolerability in Research Participants With Dentin Hypersensitivity
This single-center, randomized, double-blind, three-arm, non-inferiority clinical study will evaluate whether a toothpaste containing 20% hydroxyapatite and 2% calcium hypophosphite is clinically non-inferior to each of two active comparator toothpastes in reducing dentin hypersensitivity. One comparator contains stannous fluoride and the other contains 8% arginine. The study will also evaluate the safety and tolerability of the three toothpastes.
A total of 186 adults aged 18 to 65 years with dentin hypersensitivity will be randomly assigned in a 1:1:1 ratio to one of three treatment groups. Participants will use their assigned toothpaste twice daily for 56 days.
The primary outcome is the mean reduction in dentin hypersensitivity symptoms from baseline to Day 56, as measured by the airblast test score using a 0-to-100 mm visual analogue scale (VAS), comparing the test group separately with each of the two control groups.
Additional assessments include responses to the airblast and cold-water tests after the first toothpaste use and during follow-up, participants' subjective assessments of dentin sensitivity, adverse events, and investigator- and participant-rated efficacy and tolerability.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Only the main outcome measures and the main inclusion and exclusion criteria are listed in this record. Further secondary and exploratory endpoints as well as the complete eligibility criteria are specified in the study protocol.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Anastasia Harder
- Telefoonnummer: +49521-8808-538
- E-mail: anastasia.harder@drwolffgroup.com
Studie Locaties
-
-
Valinhos
-
São Paulo, Valinhos, Brazilië, 13270-180
- Werving
- Kosmoscience
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Men and women aged between 18 and 65 years.
- Presenting with dentin hypersensitivity.
- At least one eligible tooth (incisor, canine, premolar, or first molar) must have visibly exposed cervical dentin on the facial surface and a score at least 30 mm on the 100-mm VAS immediately after the airblast test (VAS: 0 mm: no sensitivity; 100 mm: worst imaginable sensitivity)
- Proper periodontal health (i.e. no probing depth > 4 mm, or other conditions that might explain their apparent dentin hypersensitivity
- To be in good general health, as assessed by the investigator.
Exclusion Criteria:
- Previous professional desensitizing treatment within the past 3 months (e.g., in-office fluoride varnish, laser desensitization)
- Use of over-the-counter desensitizing products within the previous 8 weeks
- Medical histories made remarkable by chronic use of antibiotics, anti-inflammatory, analgesic, anticonvulsant, sedative, and psychotropic drugs; or ongoing active treatment with any of these drug classes at the time of screening
- Pregnancy and breastfeeding
- Allergies and idiosyncratic responses to product ingredients (e.g., any ingredient of the investigational or comparator products)
- Teeth or periodontium with pathology or defects likely to cause pain (e.g., periodontal abscess, tooth mobility greater than Grade 1) (applies to teeth designated for sensitivity assessment)
Only the main eligibility criteria are listed. The complete criteria are specified in the study protocol.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: 20% Hydroxyapatite and 2% Calcium Hypophosphite Toothpaste
|
Participants will use the assigned toothpaste twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home. |
|
Actieve vergelijker: Stannous Fluoride Toothpaste
|
Participants will use a comparator toothpaste containing stannous fluoride, providing 1100 ppm fluoride, twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home. |
|
Actieve vergelijker: 8% Arginine Toothpaste
|
Participants will use a comparator toothpaste containing 8% arginine twice daily, in the morning and evening, for 56 days. For each use, the toothpaste will be applied to the entire toothbrush head, and participants will brush for 2 minutes. The first use will be performed at the study site under supervision; subsequent use will take place at home. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56
Tijdsspanne: Baseline (Day 1) to Day 56 (±3 Days)
|
The primary endpoint is the mean reduction in dentin hypersensitivity symptoms, as measured by the airblast test score (rated on a visual analogue scale, VAS [0-100]) from Baseline to Day 56 between the test group and both control groups. VAS: 0 mm: No sensitivity; 100 mm: worst imaginable sensitivity. Non-inferiority will be assessed separately for the investigational toothpaste versus each of the two comparator toothpastes, using a predefined non-inferiority margin (δ) of 10 mm on the VAS scale (0-100 mm). |
Baseline (Day 1) to Day 56 (±3 Days)
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Mean change in VAS (Cold Water Test) from Baseline to Day 56
Tijdsspanne: Baseline (Day 1) to Day 56 (±3 Days)
|
Mean change in VAS (Cold Water Test) from Baseline to Day 56 between the test group and each of the two control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Baseline (Day 1) to Day 56 (±3 Days)
|
|
Mean change in VAS (Airblast test) from Baseline to Day 28
Tijdsspanne: Baseline (Day 1) to Day 28 (±3 Days)
|
Mean change in VAS (Airblast test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Baseline (Day 1) to Day 28 (±3 Days)
|
|
Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application
Tijdsspanne: Day 1 (Baseline and directly after the first application)
|
Mean change in VAS (Airblast test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Day 1 (Baseline and directly after the first application)
|
|
Mean change in VAS (Cold Water test) from Baseline to Day 28
Tijdsspanne: Baseline (Day 1) to Day 28 (±3 Days)
|
Mean change in VAS (Cold Water Test) from Baseline to Day 28 between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Baseline (Day 1) to Day 28 (±3 Days)
|
|
Mean change in VAS (Cold Water test) from Baseline to Day 1 directly after the first application
Tijdsspanne: Day 1 (Baseline and directly after the first application)
|
Mean change in VAS (Cold Water Test) from Baseline to Day 1 directly after the first application between the test group and both control groups. Participant-rated pain intensity on a 100-mm visual analogue scale (VAS) immediately after the stimulus (0 mm: No sensitivity; 100 mm: worst imaginable sensitivity). |
Day 1 (Baseline and directly after the first application)
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Ana Lúcia Tabarini Alves Pinheiro, MD, Kosmoscience Ciência e Tecnologia Cosmética, Importação e Exportação Ltda.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- DH-03/2025
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
All data and information retrieved within the investigation are an intellectual property of the Sponsor.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .